

Optimal sequencing of enzalutamide and abiraterone ac-  
tivity in castration-resistant prostate cancer: a multicentre, ran-  
domised crossover trial

Lancet Oncology, The  
20, 1730-1739

DOI: [10.1016/s1470-2045\(19\)30688-6](https://doi.org/10.1016/s1470-2045(19)30688-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Androgen receptor-targeted agents in the management of advanced prostate cancer. <i>Lancet Oncology</i> , The, 2019, 20, 1628-1630.	5.1	1
2	Sequence of AR inhibitors affects outcome. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 69-69.	12.5	5
3	A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment. <i>BMC Cancer</i> , 2020, 20, 919.	1.1	12
4	Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0239686.	1.1	6
5	Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100193.	0.7	2
6	Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8277.	1.8	14
7	A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5338-5347.	3.2	76
8	Effect of high-fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 339-346.	1.1	4
9	Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 1349.	1.3	22
10	RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28092-28101.	3.3	20
11	Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. <i>Cancer Cell</i> , 2020, 38, 489-499.e3.	7.7	216
12	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , 2020, 26, 6122-6131.	3.2	9
13	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2345-2357.	13.9	440
15	YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients. <i>Pharmacogenomics</i> , 2020, 21, 919-928.	0.6	3
16	Management of Advanced Prostate Cancer in Clinical Practice: Real-World Answers to Challenging Dilemmas. <i>JCO Oncology Practice</i> , 2020, 16, 783-789.	1.4	6
18	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1285-1301.	1.5	42
19	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. <i>Nature Communications</i> , 2020, 11, 5549.	5.8	76
20	<p>&lt;p>Metastatic Hormone-sensitive Prostate Cancer:ÂCurrent Perspective on the Evolving Therapeutic Landscape</p>&lt;/p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3571-3581.	1.0	23

#	ARTICLE	IF	CITATIONS
21	Pharmacotherapeutic strategies for castrate-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1431-1448.	0.9	23
22	Novel therapies for advanced urologic cancers. <i>Current Opinion in Urology</i> , 2020, 30, 594-601.	0.9	2
23	Advanced Prostate Cancer: Treatment Advances and Future Directions. <i>Trends in Cancer</i> , 2020, 6, 702-715.	3.8	122
24	Abiraterone acetate plus Prednisone/Prednisolone compared with Enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real-world data (ACES). <i>BJUI Compass</i> , 2020, 1, 21-31.	0.7	1
25	Living Longer and Better with Advanced Prostate Cancer. <i>European Urology</i> , 2020, 78, 358-359.	0.9	0
26	The role of taxane-based chemotherapy in the treatment of prostate cancer. <i>Current Opinion in Urology</i> , 2020, 30, 527-533.	0.9	5
27	Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 629-638.	1.1	4
28	Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 381-397.	2.0	34
29	Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 539-548.	2.0	27
30	HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. <i>Annals of Oncology</i> , 2020, 31, 1186-1197.	0.6	26
31	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1119-1134.	0.6	485
32	Re: Olaparib for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 78, 767-768.	0.9	2
34	Does sequencing order of antiandrogens in prostate cancer matter?. <i>Nature Reviews Urology</i> , 2020, 17, 197-198.	1.9	3
35	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
37	Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?. <i>European Urology Focus</i> , 2021, 7, 752-763.	1.6	9
38	Recent progress in treating advanced prostate cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 210-215.	1.1	26
40	Homology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 917-923.	1.0	2
41	The Impact of Treatment Crossover and Prostate-specific Antigen Flare with Enzalutamide and Abiraterone in Metastatic Castrate Resistant Prostate Cancer. <i>Clinical Oncology</i> , 2021, 33, e92.	0.6	0

#	ARTICLE	IF	CITATIONS
42	Use of Chemotherapy and Androgen Signalingâ€‘targeted Inhibitors in Patients with Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 170-172.	0.9	3
43	Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 301-309.	2.0	19
45	Treatment and resistance mechanisms in castration-resistant prostate cancer: new implications for clinical decision making?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 149-163.	1.1	4
46	Overall Survival Among Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer Under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014â€‘2018 French Population Study (the SPEAR Cohort). <i>American Journal of Epidemiology</i> , 2021, 190, 413-422.	1.6	16
47	Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancerâ€‘a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3918-3930.	0.6	10
48	Finding the optimal treatment sequence in metastatic castration-resistant prostate cancerâ€‘a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3931-3945.	0.6	3
49	<i>BRCA2</i> , <i>ATM</i> , and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. <i>Clinical Cancer Research</i> , 2021, 27, 1650-1662.	3.2	52
50	Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. <i>Journal of Urology</i> , 2021, 205, 14-21.	0.2	167
51	Clinical implications of genomic alterations in metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 310-322.	2.0	12
52	Survival outcomes in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1032-1040.	2.0	28
53	Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 93, 102152.	3.4	10
54	The Real-World Experience of Single-Center, Retrospective Study of the Prognostic Effect of Secondary Hormone Agent on Survival in Patients With Hormone-Refractory Metastatic Prostate Cancer. <i>The Korean Journal of Urological Oncology</i> , 2021, 19, 48-59.	0.1	0
55	Differential treatment outcomes in <i>BRCA1/2</i> , <i>CDK12</i> , and <i>ATM</i> -mutated metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 1965-1973.	2.0	15
56	Resistance to second-generation androgen receptor antagonists in prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 209-226.	1.9	59
57	Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 634-640.	0.3	3
58	Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naïve disease. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1287-1297.	0.6	1
59	Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1174-1176.	13.9	1
60	Upregulation of glucocorticoid receptor-mediated glucose transporter 4 in enzalutamide-resistant prostate cancer. <i>Cancer Science</i> , 2021, 112, 1899-1910.	1.7	10

#	ARTICLE	IF	CITATIONS
61	Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal. <i>Current Opinion in Oncology</i> , 2021, 33, 252-256.	1.1	3
63	Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 948-961.	2.0	5
64	Endocrine therapy for cancer. <i>Surgery</i> , 2021, 39, 208-214.	0.1	0
65	Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1625-1632.	0.9	5
66	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1371-1382.	0.8	65
67	Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 3610-3619.	3.2	17
68	An up-to-date evaluation of abiraterone for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1227-1234.	0.9	3
69	Resistance to the Androgen Receptor Centred Therapies: Biology and Management. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1593-1609.	0.3	0
70	Recent Advances in the Treatment of Metastatic Prostate Cancer. <i>Advances in Oncology</i> , 2021, 1, 263-272.	0.1	1
71	2020 Korean guidelines for the management of metastatic prostate cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 491-514.	0.7	5
72	Cross-resistance and drug sequence in prostate cancer. <i>Drug Resistance Updates</i> , 2021, 56, 100761.	6.5	36
73	Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2110950.	2.8	4
74	Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1452-1461.	0.6	3
75	Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide. <i>Frontiers in Pharmacology</i> , 2021, 12, 669236.	1.6	3
76	Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 661.	1.4	7
77	Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e190-e202.	1.8	9
78	Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience. <i>Frontiers in Oncology</i> , 2021, 11, 656146.	1.3	7
79	Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. <i>Clinical Cancer Research</i> , 2021, 27, 4610-4623.	3.2	41

#	ARTICLE	IF	CITATIONS
80	Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?. <i>European Urology</i> , 2021, 79, 710-712.	0.9	9
81	Olaparib for the treatment of metastatic prostate cancer. <i>Future Oncology</i> , 2021, 17, 2413-2429.	1.1	2
82	Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds. <i>Annals of Oncology</i> , 2021, 32, 831-832.	0.6	0
83	Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation. <i>Frontiers in Oncology</i> , 2021, 11, 700543.	1.3	5
84	Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 754-763.	0.8	2
85	Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study. <i>European Journal of Cancer</i> , 2021, 152, 215-222.	1.3	11
86	A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer. <i>European Urology Open Science</i> , 2021, 29, 59-67.	0.2	4
87	Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. <i>Annals of Oncology</i> , 2021, 32, 896-905.	0.6	39
88	Metastatic prostate cancer: clinical aspects and treatment limitations in a university hospital center in Senegal. <i>African Journal of Urology</i> , 2021, 27, .	0.1	1
89	A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 131-153.	4.2	55
90	KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 3017-3026.	1.1	19
91	Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer. <i>Cancer Medicine</i> , 2021, 10, 6304-6309.	1.3	3
93	A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer. <i>Cancer Medicine</i> , 2021, 10, 6354-6364.	1.3	7
94	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. <i>Cancers</i> , 2021, 13, 4951.	1.7	19
95	Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 4.e19-4.e28.	0.8	7
96	Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 1541-1559.	5.1	60
97	Activity of New Synthetic (2-Chloroethylthio)-1,4-naphthoquinones in Prostate Cancer Cells. <i>Pharmaceuticals</i> , 2021, 14, 949.	1.7	6
98	Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. <i>Cancers</i> , 2021, 13, 4522.	1.7	22

#	ARTICLE	IF	CITATIONS
99	Evaluating the Role of Stereotactic Body Radiation Therapy With Respect to Androgen Receptor Signaling Inhibitors for Oligometastatic Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2022, 7, 100808.	0.6	4
100	Recent Advances in the Management of Metastatic Prostate Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 45-55.	1.4	75
101	Prostate cancer. <i>Lancet, The</i> , 2021, 398, 1075-1090.	6.3	240
102	Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients. <i>ESMO Open</i> , 2021, 6, 100261.	2.0	14
103	Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. <i>European Urology</i> , 2021, 80, 497-506.	0.9	16
104	Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e326-e333.	0.9	7
105	The treatment landscape of metastatic prostate cancer. <i>Cancer Letters</i> , 2021, 519, 20-29.	3.2	50
106	Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study. <i>ESMO Open</i> , 2021, 6, 100241.	2.0	13
108	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2020, 78, 834-844.	0.9	47
111	A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 13247-13263.	1.0	8
112	Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study. <i>In Vivo</i> , 2021, 35, 3509-3519.	0.6	5
113	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , 2022, 18, 35-45.	1.1	4
114	Prostatakarzinom: Die optimale Sequenz für die zweite und nachfolgende Therapielinien beim mCRPC ist noch nicht gefunden. <i>Karger Kompass Onkologie</i> , 2020, 7, 197-198.	0.0	0
115	Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer. <i>Prostate International</i> , 2021, 10, 50-55.	1.2	3
116	Anticipating the Next Challenging Clinical Dilemmas in Prostate Cancer. <i>JCO Oncology Practice</i> , 2020, 16, 791-792.	1.4	0
120	Round up. <i>Indian Journal of Urology</i> , 2020, 36, 6-7.	0.2	0
121	Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer-a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3188-3198.	0.6	1
122	Abiraterone acetate – 10 clinically relevant facts. <i>OnCOReview</i> , 2021, 11, 80-84.	0.1	0



#	ARTICLE	IF	CITATIONS
123	Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis. <i>International Journal of Clinical Oncology</i> , 2022, 27, 592-601.	1.0	7
124	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. <i>Current Oncology</i> , 2021, 28, 4894-4928.	0.9	0
125	Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	2
126	Progress in Clinical Application of Abiraterone in the Treatment of mCRPC. <i>Advances in Clinical Medicine</i> , 2021, 11, 5507-5513.	0.0	0
127	The prostate cancer landscape in Europe: Current challenges, future opportunities. <i>Cancer Letters</i> , 2022, 526, 304-310.	3.2	16
128	Prostatakarzinom: Kein harmloser Alterskrebs. , 0, , .		1
129	Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3188-3198.	0.6	3
130	Metastatic Prostate Cancer: Treatment Options. <i>Oncology</i> , 2022, 100, 48-59.	0.9	47
131	Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer. <i>BJUI Compass</i> , 2022, 3, 205-213.	0.7	6
132	Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors. <i>JMA Journal</i> , 2022, 5, 83-90.	0.6	1
133	Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 67-73.	2.0	2
134	Rational Second-Generation Antiandrogen Use in Prostate Cancer. <i>Oncologist</i> , 0, , .	1.9	10
135	Should Early Use of Chemotherapy Be Avoided in the Treatment of Metastatic Prostate Cancer?. <i>JMA Journal</i> , 2022, 5, 91-92.	0.6	0
136	Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus. <i>Oncology and Therapy</i> , 2022, 10, 143-165.	1.0	1
137	Evaluation of JQ1 Combined With Docetaxel for the Treatment of Prostate Cancer Cells in 2D- and 3D-Culture Systems. <i>Frontiers in Pharmacology</i> , 2022, 13, 839620.	1.6	4
138	Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer—Where Are We Now?. <i>Cancers</i> , 2022, 14, 801.	1.7	23
139	Managing advanced prostate cancer in the Asia Pacific region: Real-world application of Advanced Prostate Cancer Consensus Conference 2019 statements. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 686-695.	0.7	5
140	PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence. <i>Cancer Treatment Reviews</i> , 2022, 104, 102359.	3.4	9



#	ARTICLE	IF	CITATIONS
141	Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 192.e1-192.e9.	0.8	6
142	Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 306-313.	2.0	5
143	Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?. <i>Journal of Clinical Oncology</i> , 2022, 40, 1518-1521.	0.8	9
144	Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?. <i>Frontiers in Pharmacology</i> , 2022, 13, 843110.	1.6	3
145	Mismatch repair deficiency and clinical implications in prostate cancer. <i>Prostate</i> , 2022, 82, .	1.2	9
146	Targeting the androgen receptor signaling pathway in advanced prostate cancer. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1224-1235.	0.5	5
147	Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 393-398.	0.4	4
149	Real-world cabazitaxel use and outcomes in metastatic castrate-resistant prostate cancer: the impact of response to first ARPI. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	0
150	Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors. <i>CNS Drugs</i> , 2022, 36, 419-449.	2.7	6
151	Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management. <i>Current Opinion in Urology</i> , 2022, 32, 283-291.	0.9	4
152	Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management. , 2022, 39, 107.		2
154	Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial. <i>European Urology Open Science</i> , 2022, 41, 16-23.	0.2	3
155	Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease. <i>Anticancer Research</i> , 2022, 42, 3041-3047.	0.5	1
156	Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer. <i>Prostate</i> , 2022, 82, .	1.2	6
157	Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
158	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	40
159	Understanding the Current Therapeutic Landscape for Advanced Prostate Cancer (CME article). <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, .	0.0	0
160	Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axisâ€œTargeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. <i>European Urology Focus</i> , 2023, 9, 106-109.	1.6	3

#	ARTICLE	IF	CITATIONS
161	Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. <i>Nature</i> , 2022, 608, 199-208.	13.7	63
162	Second generation androgen receptor antagonists and challenges in prostate cancer treatment. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	32
163	Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic. <i>American Journal of Men's Health</i> , 2022, 16, 155798832211155.	0.7	1
164	Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience. <i>PLoS ONE</i> , 2022, 17, e0264800.	1.1	1
165	Should We "PROpel" Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?. , 2022, 1, .		0
166	m6A Methylation Regulators Are Predictive Biomarkers for Tumour Metastasis in Prostate Cancer. <i>Cancers</i> , 2022, 14, 4035.	1.7	5
167	Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry. <i>European Urology Open Science</i> , 2022, 45, 12-22.	0.2	2
168	Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer. <i>Asian Journal of Andrology</i> , 2023, 25, 366-374.	0.8	2
169	Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide. <i>Cancer Medicine</i> , 0, , .	1.3	1
170	Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 743-750.	2.0	7
171	"Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil" <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	0
172	Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. <i>European Urology</i> , 2023, 84, 4-6.	0.9	7
173	Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study. <i>Anticancer Research</i> , 2022, 42, 4857-4866.	0.5	0
174	The Value of Phenotypic Precision Medicine in Prostate Cancer. <i>Oncologist</i> , 2023, 28, 93-104.	1.9	5
176	Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	7
177	Naphthoquinones and derivatives as potential anticancer agents: An updated review. <i>Chemico-Biological Interactions</i> , 2022, 368, 110198.	1.7	24
178	A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	3
179	Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1163-1175.	1.1	6

#	ARTICLE	IF	CITATIONS
180	The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1293-1304.	1.3	0
181	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance. <i>Progres En Urologie</i> , 2022, 32, 1373-1419.	0.3	5
182	Risk of cognitive impairment in men with advanced prostate cancer treated with NHAs: A systematic review and network meta-analysis. <i>Clinical and Translational Science</i> , 2023, 16, 313-325.	1.5	3
183	Objective response rate of placebo in randomized controlled trials of anticancer medicines. <i>EClinicalMedicine</i> , 2023, 55, 101753.	3.2	4
185	Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study. <i>Targeted Oncology</i> , 0, , .	1.7	0
186	Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 665-672.	2.0	6
187	Plasma progastrin-releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis-targeted agents in patients with metastatic castration-resistant prostate cancer. <i>Cancer Reports</i> , 0, , .	0.6	1
188	Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors. <i>Cancer Science</i> , 2023, 114, 1625-1634.	1.7	2
189	Prevalence and Causes of Discontinuation of Androgen Receptor Inhibitors in Advanced Prostate Cancer Patients and Analysis of Physician Management to Increase Duration of Therapy. <i>Urology</i> , 2023, 173, 142-148.	0.5	1
190	Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review. <i>World Journal of Men's Health</i> , 2023, 41, 769.	1.7	10
191	Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). <i>Journal of Clinical Oncology</i> , 2023, 41, 3608-3615.	0.8	2
192	Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 3339-3351.	0.8	60
193	Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2023, 83, 584-585.	0.9	0
194	Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 349-356.e2.	0.9	1
195	Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study. <i>European Urology</i> , 2023, , .	0.9	0
197	How to Optimally Sequence Available Therapy Lines in Advanced Prostate Cancer. <i>Acta Clinica Croatica</i> , 2022, , .	0.1	0
198	Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2023, , .	1.5	1
199	Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study. <i>Oncologist</i> , 2023, 28, e737-e747.	1.9	2

#	ARTICLE	IF	CITATIONS
215	Metastasiertes kastrationsresistentes Prostatakarzinom mit Therapiesequenz (mCRPC). , 2023, , 77-92.		0
225	Malignome des Urogenitaltrakts. , 2024, , 801-864.		0